Business Description
Medivir AB
ISIN : SE0020181014
Share Class Description:
OSTO:MVIR: Ordinary SharesTotal Employee Number:
7Compare
Compare
Traded in other countries / regions
MVIR.Sweden0GP7.UKMVR0.Germany IPO Date
1996-02-29Description
Medivir AB develops therapies targeting diseases with high unmet medical need. The group's drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Its two programs are fostrox, designed to target liver cancer cells while minimizing side effects selectively, and MIV-711, aimed at treating Osteogenesis Imperfecta (Brittle bone disease) and Legg-Calve-Perthes disease (Perthes disease). It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. It also has four out-licensed projects, Xerclear, MIV-701, MBLI/MET-X, and remetinostat. Geographic revenue is generated from Europe and other regions.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 17.77 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.15 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 11.5 | |||||
Beneish M-Score | -2.3 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.8 | |||||
3-Year EBITDA Growth Rate | 35.2 | |||||
3-Year EPS without NRI Growth Rate | 25.1 | |||||
3-Year FCF Growth Rate | 34.6 | |||||
3-Year Book Growth Rate | -50.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -9.61 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.83 | |||||
9-Day RSI | 54.29 | |||||
14-Day RSI | 53.28 | |||||
3-1 Month Momentum % | -4.52 | |||||
6-1 Month Momentum % | 302.21 | |||||
12-1 Month Momentum % | -7.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.34 | |||||
Quick Ratio | 5.34 | |||||
Cash Ratio | 5.2 | |||||
Days Sales Outstanding | 156.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -87.5 | |||||
Shareholder Yield % | -3.99 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1006.74 | |||||
Net Margin % | -1016.85 | |||||
EBITDA Margin % | -640.45 | |||||
FCF Margin % | -669.66 | |||||
OCF Margin % | -669.66 | |||||
ROE % | -76.22 | |||||
ROA % | -53.55 | |||||
ROIC % | -67.03 | |||||
3-Year ROIIC % | 12.66 | |||||
ROC (Joel Greenblatt) % | -1174.34 | |||||
ROCE % | -71.07 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 38.29 | |||||
PB Ratio | 5.07 | |||||
Price-to-Tangible-Book | 7.83 | |||||
EV-to-EBIT | -11.18 | |||||
EV-to-EBITDA | -17.57 | |||||
EV-to-Revenue | 112.53 | |||||
EV-to-Forward-Revenue | 113.61 | |||||
EV-to-FCF | -15.95 | |||||
Price-to-GF-Value | 1.62 | |||||
Price-to-Median-PS-Value | 1.4 | |||||
| Price-to-Net-Current-Asset-Value | 8.18 | |||||
| Price-to-Net-Cash | 8.57 | |||||
Earnings Yield (Greenblatt) % | -8.96 | |||||
FCF Yield % | -5.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medivir AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 8.9 | ||
| EPS (TTM) (kr) | -0.54 | ||
| Beta | 0.6745 | ||
| 3-Year Sharpe Ratio | 0.19 | ||
| 3-Year Sortino Ratio | 0.52 | ||
| Volatility % | 266.59 | ||
| 14-Day RSI | 53.28 | ||
| 14-Day ATR (kr) | 0.089388 | ||
| 20-Day SMA (kr) | 1.7506 | ||
| 12-1 Month Momentum % | -7.53 | ||
| 52-Week Range (kr) | 0.34 - 2.885 | ||
| Shares Outstanding (Mil) | 617.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medivir AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medivir AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 15:00 | In 95 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 94 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 | In 16 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 16 days | ||
| General meeting for 2026 | 2026-05-07 14:00 | 1.82 (-3.70%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 14:00 | 1.88 (-1.57%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 1.88 (-1.57%) | ||
| Annual report for 2025 | 2026-04-01 | 2.48 (+4.20%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-18 14:00 | 1.00 (-9.26%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-18 | 1.00 (-9.26%) |
Show
Entries
Medivir AB Frequently Asked Questions
What is Medivir AB(OSTO:MVIR)'s stock price today?
The current price of OSTO:MVIR is kr1.80. The 52 week high of OSTO:MVIR is kr2.89 and 52 week low is kr0.34.
When is next earnings date of Medivir AB(OSTO:MVIR)?
The next earnings date of Medivir AB(OSTO:MVIR) is 2026-08-20.
Does Medivir AB(OSTO:MVIR) pay dividends? If so, how much?
Medivir AB(OSTO:MVIR) does not pay dividend.
Press Release
Articles on Medivir AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers